Biocon informs about updates

07 Oct 2025 Evaluate

Biocon has informed that Biocon Pharma, a wholly owned subsidiary of the Company, in partnership with Carnegie Pharmaceuticals LLC, received tentative approval from the U.S. Food and Drug Administration (U.S. FDA) for the ANDA for Rifaximin Tablets, 550 mg. Rifaximin tablets are a rifamycin antibacterial indicated for reducing the risk of overt hepatic encephalopathy (HE) recurrence and to treat irritable bowel syndrome with diarrhea (IBS-D) in adults. 

The above information is a part of company’s filings submitted to BSE.

Biocon Share Price

361.25 -8.85 (-2.39%)
30-Mar-2026 12:39 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1781.50
Dr. Reddys Lab 1267.80
Cipla 1233.95
Zydus Lifesciences 889.35
Lupin 2328.65
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×